loader2
Partner With Us NRI

Aarti Drugs Ltd share Price Today

Company details

515.55
525.00
431.05
645.75
6M Return 8.81%
1Y Return 14.76%
Mkt Cap.(Cr) 4,795.79
Volume 189,738
Div Yield 0.19%
OI
-
OI Chg %
-
Volume 189,738

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Aarti Drugs announced consolidated Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Revenue stood at Rs 621.1 crore as against Rs 743.3 crore, a decline of 16.4% YoY
  • EBITDA stood at Rs 86.9 crore as against Rs 94.4 crore YoY. EBITDA Margin (%) came in at 14.0%
  • PAT stood at Rs 47.3 crore as against Rs 56.2 crore YoY. PAT Margin (%) stood at 7.6%

FY24 Financial Highlights:

  • Revenue stood at Rs 2,532.6 crore as against Rs 2,718.2 crore, a decline of 6.8% YoY
  • EBITDA stood at Rs 320.5 crore as against Rs 307.8 crore YoY. EBITDA Margin (%) came in at 12.7%
  • PAT stood at Rs 171.6 crore as against Rs 166.4 crore YoY. PAT Margin (%) stood at 6.8%

Commenting on the same, Adhish Patil, CFO & COO, Aarti Drugs said, “We are pleased with our financial and operational performance in FY24 amid geopolitical uncertainties and macroeconomic factors and price volatilities. The company demonstrated resilient performance in FY24, where topline declined by 7% YoY during full year FY24, attributed to lower realizations stemming from negative rate variance and subdued export market demand in APIs business. However, there has been a notable improvement in gross margins, credited to the stabilization of input costs in latter half of FY24 and operational efficiencies across the majority of our product lines. Furthermore, we anticipate a further enhancement in gross margins in future, mostly driven by upturn in selling price levels and an anticipated growth in export sales. EBITDA Margin for FY24 improved by ~140 basis points and PAT margins improved by ~70 basis points due to improved gross contributions in standalone as well as formulation business along with efficient working capital management.

For Q4FY24, the company’s performance improved considerably on a sequential basis due to ease in the input costs and better product mix. On a sequential basis, the EBITDA margins improved by ~220 bps due to operating leverage driven by improved capacity utilization.

Amidst heightened interest rates, dollar shortages, destocking, supply chain hurdles, and conservative ordering, export demand encountered challenges in select regions during Q4 and FY24. Nonetheless, we anticipate a positive shift in the export landscape in the near future, on back of interest rate reductions, low stock levels and an upswing in demand. Despite these hurdles, our outlook remains optimistic, on attaining our growth and margin targets.

Formulation segment’s revenue stood at Rs 67.6 crore for the quarter, a growth of 19% YoY with exports contribution of ~62%. In FY24 revenues stood at Rs 324.6 crore, with growth of 18.5% YoY

In the Specialty Chemical industry, although India's domestic chemicals demand is projected to remain robust in 2024, with low expectations in price increase. The market faces various challenges of finding equilibrium amidst the introduction of new production capacities within the country, shifting trade dynamics, subdued global demand, and fluctuating upstream prices.

The company’s balance sheet continued to remain healthy with leverage remaining comfortably at 0.44x.

The capex for FY24 stood at ~Rs. 226 crore. Recently, Greenfield project at Tarapur Facility for dermatology products has been commenced and the ramp up is planned throughout H1 FY25. Greenfield Project at Gujarat Sayakha for Speciality Chemicals is on track which we plan to commence by end of Q1 FY25. With this, the operating leverage is expected to kick in from H2 FY25 with improved capacity utilization.

The company has incurred a capex of ~ Rs 543 crore in the last 3 years, mainly towards capacity expansion, backward integration and new product launches across API & Formulation segment. The majority of the company’s ? 600 crore capex has been completed and balance is expected to be completed soon. These initiatives are expected to reduce the costs along with expansion in the profit margins and the topline growth.

The Pharma API manufacturing industry is constantly evolving, and we are committed to staying ahead of the curve. In the upcoming year, we plan to continue expanding our capabilities and enhancing our offerings to meet the ever-changing needs of our customers. One of our key goals for the upcoming year is to improve our capacity utilisation, allowing us to better serve our growing customer base. We also plan to invest in new technologies and equipment that will help us streamline our processes, reduce carbon footprint and improve efficiency.”

Result PDF

View Other Company Results

Aarti Drugs Ltd shares SWOT Analysis

Strengths (9)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Rising Net Cash Flow and Cash from Operating activity
  • Growth in Net Profit with increasing Profit Margin (QoQ)

Weakness (6)

  • MFs decreased their shareholding last quarter
  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of shareholder funds - ROE declining in the last 2 years

Opportunity (1)

  • RSI indicating price strength

Threats (2)

  • Promoter decreasing their shareholding
  • Big Deal (Insider and SAST) sells last month greater than 1% of total shares

Resistance and support

R1 525.9
R2 530.2
R3 535.4
Pivot

520.73

S1 516.5
S2 511.3
S3 507.0
EMA SMA
501.2
494.2
494.7
494.7
497.4
493.5
496.0
506.1
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
BLEND FUND 2 Bulk Purchase 2024-05-28 484.97 511571 NSE
MIRIK RAJENDRA GOGRI Bulk Sell 2024-05-28 485.5 468378 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2023-10-18 554.17 480077 NSE
Name Category Shares
Prakash Moreshwar Patil PROMOTER 9.24%
Harshit Manilal Savla PROMOTER 4.74%
Rashesh Chandrakant Gogri PROMOTER 4.65%
Priti Prakash Patil PROMOTER 4.4%
Seema Harshit Savla PROMOTER 3.84%
Hetal Gogri Gala PROMOTER 3.06%
Chandrakant Vallabhaji Gogri PROMOTER 1.87%
Jaya Chandrakant Gogri PROMOTER 1.71%
Mirik Rajendra Gogri PROMOTER 1.31%
Renil Rajendra Gogri PROMOTER 1.25%
Adhish P. Patil PROMOTER 1.24%
Bhoomi Harshit Savla PROMOTER 1.09%
Vishwa Harshit Savla PROMOTER 1.03%
Aashay Rashesh Gogri PROMOTER 0.96%
Rajendra Vallabhaji Gogri PROMOTER 0.52%
Gogri Finserv Pvt. Ltd. PROMOTER 3.8%
Anushakti Enterprise Private Limited PROMOTER 2.62%
Alchemie Finserv Pvt. Ltd. PROMOTER 2.21%
Aashyav Business Trust (Alabhya Trusteeship Private Limited) PROMOTER 1.5%
Tulip Family Trust (Gloire Trusteeship Services Private Limited) PROMOTER 1.01%
Orchid Family Trust (Relacion Trusteeship Services Private Limited) PROMOTER 0.99%
Paridhi Business Trust (Saswat Trusteeship Private Limited) PROMOTER 0.64%
Safechem Enterprises Private Limited PROMOTER 0.61%
Dilesh Roadlines Pvt Ltd PROMOTER 0.54%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Aarti Drugs Ltd Stocks COMPARISON

Financials( in Cr) Aarti Drugs Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 521.65 1,520.95 1,574.80 4,564.50 1,078.95
% Change 0.09 0.33 0.64 -0.53 -2.76
Mcap Cr 4,795.79 364,926.86 127,144.16 121,173.33 108,567.62
Revenue TTM Cr 2,716.05 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr 166.36 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 27.92 36.34 29.68 76.10 28.94
1 Year Return 14.76 54.15 60.91 30.94 102.68
ROCE 15.29 16.79 14.76 19.30 16.25
ROE 14.93 16.46 10.66 14.89 14.05
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 1,192.43 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 32,452.94 -2,589.17
LAST 3M 105,794.56 -32,067.62
LAST 6M 178,880.68 -18,917.36
LAST 12M 290,144.87 98,834.05

Aarti Drugs Ltd Information

Stock PE (TTM)
27.92
Promoter Holding
57.13%
Book Value
139.3969
ROCE
15.29%
ROE
14.93%
Description
  • Aarti Drugs Ltd is in the Pharmaceuticals sector with the Market Capitalization of worth Rs. 5,768.98 crores, it is incorporated in the year 1984. It features consolidated sales of Rs. 579.95 crores in June 2021. It is also listed in the Bombay Stock Exchange (BSE) with the code 524348 and listed in the National Stock Exchange (NSE) with the code AARTIDRUGS.

    Aarti Drugs Ltd was incorporated as a private limited company on 28th September ’1984 and converted into a public limited company in 1992. It is owned by Aarti Industries Ltd, which also owns a Research & Development plant in Tarapur, Maharashtra. The Company is engaged in manufacturing Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and produces Formulations with its wholly-owned subsidiary – Pinnacle Life Science Private Limited. The Company operates through eight manufacturing facilities, two of which are strategically located in the state of Gujarat and Maharashtra. Also, all the manufacturing units of Aarti Industries are GMP certified, and therefore, the Company is additionally in the process of acquiring certification as per ISO 9002 compliance standard for all its units, out of which one has received the certification. The promoters of the Company currently hold 60.14% of the stake in the Company, while the Foreign Institutional Investors (FII) and Domestic Institutional Investors (DII) hold 2.57% and 2% of the stake. The balance of 35.29% is held by others (retail investors).

    In June 2021, quarterly net sales were Rs. 505.79 crores, which has increased by approximately 6.36% from Rs. 475.55 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 45.54 crores, which has fallen by 37.64% from a net profit of Rs. 73.03 crores in June 2020. In June 2021, the operating profit was Rs. 429.79 crores, which is also increased by 3.51% as compared to the operating profit of Rs. 415.22 crores for the quarter ending in June 2020. From Rs. 31.34 in June 2020, the EPS of Aarti Drugs has been reduced to just Rs. 4.9 per share in June 2021. AARTIDRUGS’s stock closed at Rs. 634.80 on 16th August’2021 (NSE) and has returned -1.50% in the last six months and -70.23% in the last year.

Registered Address

Plot No N-198 MIDC Tarapur, Pamtembhi Village Palghar Tal, Thane, Maharashtra, 401506

Tel : 91-22-24072249
Email : investorrelations:aartidrugs.com
Website : http://www.aartidrugs.com
Registrar

Sharepro Services

AGM Date (Month) : Sep
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 524348
NSE Code : AARTIDRUGS
Book Closure Date (Month) :
BSE Group : A
ISIN : INE767A01016

FAQ’s on Aarti Drugs Ltd Shares

You can buy Aarti Drugs Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Aarti Drugs Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 18, 2024 03:54 PM the closing price of Aarti Drugs Ltd was Rs.521.65.

The latest PE ratio of Aarti Drugs Ltd as of Jun 18, 2024 03:54 PM is 27.92

The latest PB ratio of Aarti Drugs Ltd as of Jun 18, 2024 03:54 PM is 0.27

The 52-week high of Aarti Drugs Ltd share price is Rs. 645.75 while the 52-week low is Rs. 431.05

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 18, 2024 03:54 PM, the market cap of Aarti Drugs Ltd stood at Rs. 4,795.79.

Download App

Download Our App

Play Store App Store
market app